These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34679189)

  • 1. Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome.
    van Hoogdalem MW; Johnson TN; McPhail BT; Kamatkar S; Wexelblatt SL; Ward LP; Christians U; Akinbi HT; Vinks AA; Mizuno T
    Clin Pharmacol Ther; 2022 Feb; 111(2):496-508. PubMed ID: 34679189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Verification of a Full Physiologically Based Pharmacokinetic Model for Sublingual Buprenorphine in Healthy Adult Volunteers that Accounts for Nonlinear Bioavailability.
    van Hoogdalem MW; Tanaka R; Johnson TN; Vinks AA; Mizuno T
    Drug Metab Dispos; 2024 Jul; 52(8):785-796. PubMed ID: 38769016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches.
    McPhail BT; Emoto C; Butler D; Fukuda T; Akinbi H; Vinks AA
    J Clin Pharmacol; 2021 Jul; 61(7):857-870. PubMed ID: 33382111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salivary Therapeutic Monitoring of Buprenorphine in Neonates After Maternal Sublingual Dosing Guided by Physiologically Based Pharmacokinetic Modeling.
    Alsmadi MM
    Ther Drug Monit; 2024 Aug; 46(4):512-521. PubMed ID: 38366333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.
    Kalluri HV; Zhang H; Caritis SN; Venkataramanan R
    Br J Clin Pharmacol; 2017 Nov; 83(11):2458-2473. PubMed ID: 28688108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.
    Ng CM; Dombrowsky E; Lin H; Erlich ME; Moody DE; Barrett JS; Kraft WK
    Pharmacotherapy; 2015 Jul; 35(7):670-80. PubMed ID: 26172282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics.
    van Hoogdalem MW; McPhail BT; Hahn D; Wexelblatt SL; Akinbi HT; Vinks AA; Mizuno T
    Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):87-103. PubMed ID: 33049155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methadone dosing strategies in preterm neonates can be simplified.
    van Donge T; Samiee-Zafarghandy S; Pfister M; Koch G; Kalani M; Bordbar A; van den Anker J
    Br J Clin Pharmacol; 2019 Jun; 85(6):1348-1356. PubMed ID: 30805946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voriconazole greatly increases the exposure to oral buprenorphine.
    Fihlman M; Hemmilä T; Hagelberg NM; Backman JT; Laitila J; Laine K; Neuvonen PJ; Olkkola KT; Saari TI
    Eur J Clin Pharmacol; 2018 Dec; 74(12):1615-1622. PubMed ID: 30167757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome.
    van Hoogdalem MW; Wexelblatt SL; Akinbi HT; Vinks AA; Mizuno T
    Pharmacol Ther; 2022 Jun; 234():108045. PubMed ID: 34813863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial.
    Kraft WK; Gibson E; Dysart K; Damle VS; Larusso JL; Greenspan JS; Moody DE; Kaltenbach K; Ehrlich ME
    Pediatrics; 2008 Sep; 122(3):e601-7. PubMed ID: 18694901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route.
    Kharidia J; Howgate EM; Laffont CM; Liu Y; Young MA
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1064-1074. PubMed ID: 33750027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Care-by-parent model as a tool for reduction of neonatal opioid withdrawal syndrome in neonates exposed to buprenorphine maintenance therapy in-utero.
    Lawlor ML; Shook LA; McQuerry K; Srinivasan A; Johnson QB; Chavan NR; Critchfield AS
    J Matern Fetal Neonatal Med; 2020 Aug; 33(16):2718-2722. PubMed ID: 30563376
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessing Neonatal Opioid Withdrawal Syndrome Severity as a Function of Maternal Buprenorphine Dose and Umbilical Cord Tissue Concentrations.
    Rana D; McLeod AR; Gaston PK; Hill DM; Pourcyrous M
    Ann Pharmacother; 2023 Aug; 57(8):892-898. PubMed ID: 36321504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-release versus oral buprenorphine as opioid maintenance treatment during pregnancy-maternal and neonatal outcomes.
    Kanervo M; Tupola S; Nikkola E; Rantakari K; Kahila H
    Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():106-110. PubMed ID: 38608352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forecasting Fetal Buprenorphine Exposure through Maternal-Fetal Physiologically Based Pharmacokinetic Modeling.
    van Hoogdalem MW; Tanaka R; Abduljalil K; Johnson TN; Wexelblatt SL; Akinbi HT; Vinks AA; Mizuno T
    Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between Individual versus Community-level Social Vulnerability and Neonatal Opioid Withdrawal Syndrome among Pregnant Individuals Receiving Buprenorphine for Opioid Use Disorder.
    Mason I; Abdelwahab M; Stiles A; Wu J; Venkatesh KK; Rood KM
    Am J Perinatol; 2024 May; 41(S 01):e3157-e3163. PubMed ID: 37890511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients.
    McPhail BT; Emoto C; Fukuda T; Butler D; Wiles JR; Akinbi H; Vinks AA
    J Clin Pharmacol; 2020 Apr; 60(4):453-465. PubMed ID: 31820437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo.
    Johnson TN; Howgate EM; de Wildt SN; Turner MA; Rowland Yeo K
    Drug Metab Dispos; 2023 Aug; 51(8):1035-1045. PubMed ID: 37169511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically-based pharmacokinetic modelling to investigate the effect of CYP3A4/3A5 maturation on tacrolimus pharmacokinetics in paediatric HSCT patients.
    Guan Y; Liu X; Huang K; Wang Y; Qiu K; Wang X; Huang M; Zhou D; Yu X; Zhong G
    Eur J Pharm Sci; 2024 Oct; 201():106839. PubMed ID: 38906231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.